s ystolic h eart failure treatment with the i f inhibitor ivabradine t rial
DESCRIPTION
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of ivabradine . A SHIFT study analysis. - PowerPoint PPT PresentationTRANSCRIPT
Systolic Heart failure treatment with
the If inhibitor ivabradine Trial
Clinical profiles and outcomes of patients
with chronic heart failure and chronic
obstructive pulmonary disease: efficacy
and safety of ivabradine.
A SHIFT study analysis
www.shift-study.comTavazzi L, et al. Int J Cardiol. 2013. Dec 10;170(2):182-188
Effect of ivabradine on composite of CV death or HF hospitalization
00 6 12 18 24
10
20
30
40
50
5
15
25
35
45
Pati
en
ts (
%)
Time (months)
COPD (ivabradine)
Non-COPD (ivabradine)
COPD (placebo)
Non-COPD (placebo)
Ivabradine is safe and effective in lowering the relative risk of the primary composite end point in both COPD and non-COPD patients
Tavazzi L et al. Int J Cardiol. 2013. Dec 10;170(2):182-188 www.shift-study.com